SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?
- PMID: 29291819
- DOI: 10.1016/j.kint.2017.07.008
SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?
Abstract
Sodium glucose cotransporter 2 inhibitors are a relatively new adjunctive treatment option for type 2 diabetes (T2D). Extraglycemic benefits of sodium glucose cotransporter 2 inhibition include weight and blood pressure reduction. Cherney et al. now demonstrate that these extraglycemic properties of empagliflozin are preserved despite reduced urinary glucose excretion in advancing chronic kidney disease. Limited therapeutic options for patients with type 2 diabetes in the latter stages of chronic kidney disease make empagliflozin an attractive therapeutic agent with additional cardiovascular benefits.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Comment on
-
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.Kidney Int. 2018 Jan;93(1):231-244. doi: 10.1016/j.kint.2017.06.017. Epub 2017 Aug 30. Kidney Int. 2018. PMID: 28860019
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
